A5009312809- Epigenetics and DNA Methylation
- Genomics and Chromatin Dynamics
- Cancer Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Microtubule and mitosis dynamics
- Glutathione Transferases and Polymorphisms
- Protein Degradation and Inhibitors
Yale University
2022-2024
University of New Haven
2024
Stanford University
2018
Abstract The brain is a major sanctuary site for metastatic cancer cells that evade systemic therapies. Through pre-clinical pharmacological, biological, and molecular studies, we characterize the functional link between drug resistance central nervous system (CNS) relapse in Epidermal Growth Factor Receptor- (EGFR-) mutant non-small cell lung cancer, which can progress when treated with CNS-penetrant EGFR inhibitor osimertinib. Despite widespread osimertinib distribution vivo, microvascular...
Abstract The molecular subtypes of breast cancer—defined by estrogen-receptor, progesterone-receptor, and human epidermal growth factor receptor status—have established differences in mutational profiles, prognoses, response to standard treatments. However, the evolutionary trajectories underlying these are not well understood. Knowledge differential would empower predictive modeling treatment benefit. To characterize trajectories, we first aggregated a multi-institutional cohort 23, 247...
Abstract Approximately 70% of patients diagnosed with non-small cell lung cancer (NSCLC) are not eligible for curative resection, often due to disseminated disease at diagnosis. Thus, the advent novel therapeutics, especially those efficacious metastatic disease, is primary importance. Metastasis correlates epigenetic alterations that drive tumor plasticity and adaptive heterogeneity in response multiple microenvironments cells see, yet molecular mechanisms underlying these remain poorly...